Literature DB >> 27811850

Antigen receptor stereotypy in chronic lymphocytic leukemia.

K Stamatopoulos1,2, A Agathangelidis1,3, R Rosenquist2, P Ghia3.   

Abstract

The discovery of almost identical or 'stereotyped' B-cell receptor immunoglobulins (BcR IG) among unrelated patients with chronic lymphocytic leukemia (CLL) cemented the idea of antigen selection in disease ontogeny and evolution. The systematic analysis of the stereotypy phenomenon in CLL revealed that around one-third of CLL patients may be grouped into subsets based on shared sequence motifs within the variable heavy complementarity determining region 3. Stereotyped subsets display a strikingly similar biology of the leukemic clones, referring to many different levels, from the immunogenetic and genetic and extending to the epigenetic and functional levels. Even more importantly, the homogeneity of stereotyped subsets has clinical consequences as patients assigned to the same stereotyped subset generally exhibit an overall similar disease course and outcome. In other words, stereotypy-based patient classification of CLL has already provided a more compartmentalized view of this otherwise heterogeneous disease and can assist in refining prognostication models. While this is relevant only for the one-third of cases expressing stereotyped BcR IG; in principle, however, the findings from further analysis of the stereotyped subsets may also contribute towards improved understanding of the remaining non-stereotyped fraction of CLL patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27811850     DOI: 10.1038/leu.2016.322

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  99 in total

Review 1.  Anti-DNA antibodies: aspects of structure and pathogenicity.

Authors:  Y J Jang; B D Stollar
Journal:  Cell Mol Life Sci       Date:  2003-02       Impact factor: 9.261

2.  Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.

Authors:  Emanuela M Ghia; Sonia Jain; George F Widhopf; Laura Z Rassenti; Michael J Keating; William G Wierda; John G Gribben; Jennifer R Brown; Kanti R Rai; John C Byrd; Neil E Kay; Andrew W Greaves; Thomas J Kipps
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

3.  Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins.

Authors:  Anastasia Athanasiadou; Kostas Stamatopoulos; Maria Gaitatzi; Niki Stavroyianni; Athanasios Fassas; Achilles Anagnostopoulos
Journal:  Haematologica       Date:  2008-03       Impact factor: 9.941

4.  A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies.

Authors:  Anna Lanemo Myhrinder; Eva Hellqvist; Ekaterina Sidorova; Anita Söderberg; Helen Baxendale; Charlotte Dahle; Kerstin Willander; Gerard Tobin; Eva Bäckman; Ola Söderberg; Richard Rosenquist; Sohvi Hörkkö; Anders Rosén
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

Review 5.  The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Semin Cancer Biol       Date:  2015-05-09       Impact factor: 15.707

Review 6.  Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.

Authors:  Michael Hallek
Journal:  Am J Hematol       Date:  2015-05       Impact factor: 10.047

7.  Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.

Authors:  Gerard Tobin; Ulf Thunberg; Anna Johnson; Inger Eriksson; Ola Söderberg; Karin Karlsson; Mats Merup; Gunnar Juliusson; Juhani Vilpo; Gunilla Enblad; Christer Sundström; Göran Roos; Richard Rosenquist
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

8.  TP53 mutation and survival in chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Barbara Eichhorst; Raymonde Busch; Tina Denzel; Sonja Häbe; Dirk Winkler; Andreas Bühler; Jennifer Edelmann; Manuela Bergmann; Georg Hopfinger; Manfred Hensel; Michael Hallek; Hartmut Döhner; Stephan Stilgenbauer
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

9.  Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis.

Authors:  Fiona Murray; Nikos Darzentas; Anastasia Hadzidimitriou; Gerard Tobin; Myriam Boudjogra; Cristina Scielzo; Nikolaos Laoutaris; Karin Karlsson; Fanny Baran-Marzsak; Athanasios Tsaftaris; Carol Moreno; Achilles Anagnostopoulos; Federico Caligaris-Cappio; Dominique Vaur; Christos Ouzounis; Chrysoula Belessi; Paolo Ghia; Fred Davi; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

10.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Authors:  Wendy Béguelin; Relja Popovic; Matt Teater; Yanwen Jiang; Karen L Bunting; Monica Rosen; Hao Shen; Shao Ning Yang; Ling Wang; Teresa Ezponda; Eva Martinez-Garcia; Haikuo Zhang; Yupeng Zheng; Sharad K Verma; Michael T McCabe; Heidi M Ott; Glenn S Van Aller; Ryan G Kruger; Yan Liu; Charles F McHugh; David W Scott; Young Rock Chung; Neil Kelleher; Rita Shaknovich; Caretha L Creasy; Randy D Gascoyne; Kwok-Kin Wong; Leandro Cerchietti; Ross L Levine; Omar Abdel-Wahab; Jonathan D Licht; Olivier Elemento; Ari M Melnick
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

View more
  37 in total

1.  Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Authors:  Julio Delgado; Ferran Nadeu; Dolors Colomer; Elias Campo
Journal:  Haematologica       Date:  2020-07-02       Impact factor: 9.941

2.  Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.

Authors:  Elisa ten Hacken; Maria Gounari; Jaap Willem Back; Ekaterina Shimanovskaya; Lydia Scarfò; Ekaterina Kim; Jared Burks; Maurilio Ponzoni; Giuseppe Alvise Ramirez; William G Wierda; Zeev Estrov; Michael J Keating; Alessandra Ferrajoli; Kostas Stamatopoulos; Paolo Ghia; Jan A Burger
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

3.  Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia.

Authors:  Ilaria Del Giudice; Robin Foà
Journal:  Haematologica       Date:  2019-02       Impact factor: 9.941

4.  SnapShot: Chronic Lymphocytic Leukemia.

Authors:  Elisa Ten Hacken; Romain Guièze; Catherine J Wu
Journal:  Cancer Cell       Date:  2017-11-13       Impact factor: 31.743

5.  Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).

Authors:  Sonia Jaramillo; Andreas Agathangelidis; Christof Schneider; Jasmin Bahlo; Sandra Robrecht; Eugen Tausch; Johannes Bloehdorn; Manuela Hoechstetter; Kirsten Fischer; Barbara Eichhorst; Valentin Goede; Michael Hallek; Hartmut Döhner; Richard Rosenquist; Paolo Ghia; Kostas Stamatopoulos; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2019-12-26       Impact factor: 9.941

6.  Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL.

Authors:  Gonzalo Blanco; Anna Vardi; Anna Puiggros; Andrea Gómez-Llonín; Manuel Muro; María Rodríguez-Rivera; Evangelia Stalika; Eugenia Abella; Eva Gimeno; Manuela López-Sánchez; Alicia Senín; Xavier Calvo; Pau Abrisqueta; Francesc Bosch; Ana Ferrer; Kostas Stamatopoulos; Blanca Espinet
Journal:  Oncoimmunology       Date:  2018-02-20       Impact factor: 8.110

7.  Noncatalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells.

Authors:  Martin Wist; Laura Meier; Orit Gutman; Jennifer Haas; Sascha Endres; Yuan Zhou; Reinhild Rösler; Sebastian Wiese; Stephan Stilgenbauer; Elias Hobeika; Yoav I Henis; Peter Gierschik; Claudia Walliser
Journal:  J Biol Chem       Date:  2020-03-17       Impact factor: 5.157

Review 8.  Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Authors:  Jan A Burger; Adrian Wiestner
Journal:  Nat Rev Cancer       Date:  2018-01-19       Impact factor: 60.716

9.  IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.

Authors:  Ferran Nadeu; Romina Royo; Guillem Clot; Martí Duran-Ferrer; Alba Navarro; Silvia Martín; Junyan Lu; Thorsten Zenz; Tycho Baumann; Pedro Jares; Xose S Puente; José I Martín-Subero; Julio Delgado; Elías Campo
Journal:  Blood       Date:  2021-05-27       Impact factor: 22.113

10.  Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.

Authors:  Emily Weiss; Robert Sarnovsky; Mitchell Ho; Evgeny Arons; Robert Kreitman; Evan Angelus; Antonella Antignani; David FitzGerald
Journal:  Antib Ther       Date:  2018-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.